Zydus Secures USFDA Clearance for Budesonide Capsules 4 mg

Zydus Lifesciences Limited has been provisionally granted by the US FDA to its 4mg Budesonide a delayed release capsule which is a move that would make the company broaden its market in the U.S. generics sector.

The product that has been approved is a generic of Tarpeyo Capsules, 4 mg, but is applied in treating inflammatory bowel diseases.

Budesonide is used where there is mild to moderate active Crohn disease that involves the ileum and the ascending colon. It is accepted to practice in both adults and children of eight years and above, and is thus a good way of treatment in the management of this chronic illness.

Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation

These Budesonide capsules will be produced at Zydus Pharmaceuticals Ltd, SEZ-II, the facility of the company that produces the drug with the highest standards in terms of production and which meets the requirements of the international standards. This new approval gives Zydus Lifesciences even more power to build its pipeline in the United States.

This has now seen the company attain 425 approvals by the U.S. Food and Drug Administration and this has been a steady development since it started to submit Abbreviated New Drug Applications (ANDAs) in FY 200304. To date, Zydus has registered 487 ANDAs and this is a sign of its gradual development and commitment to diversify its global generics business.

This provisional authorization of Budesonide delayed-release capsules speaks to the desire of Zydus Lifesciences to become a company that provides high-quality and affordable healthcare solutions and establishes the company as a significant player in the global pharmaceutical industry.